Floatz logo

185 assets in Pancreatic Adenocarcinoma

Therapeutic assets addressing Pancreatic Adenocarcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

AssetSponsorPhaseRating
Fluorouracilum
Pancreatic Adenocarcinoma
Jonsson Comprehensive Cancer CenterP4BBB (74)
Docetaxel
Pancreatic Adenocarcinoma
Bristol-Myers SquibbP2BBB (72)
Irinotecan
Pancreatic Adenocarcinoma
Jonsson Comprehensive Cancer CenterP3BB (71)
Oxaliplatin
Pancreatic Adenocarcinoma
Jonsson Comprehensive Cancer CenterP4BB (71)
Capecitabine
Pancreatic Adenocarcinoma
Zhejiang UniversityP4BB (68)
Olaparib
Pancreatic Adenocarcinoma
Lantern Pharma Inc.P3BB (68)
Daraxonrasib
Pancreatic Adenocarcinoma
Revolution Medicines, Inc.P3BB (66)
Irinotecan Sucrosofate
Pancreatic Adenocarcinoma
SWOG Cancer Research NetworkP3BB (66)
Cis-Diamminedichloroplatinum Ii
Pancreatic Adenocarcinoma
Jonsson Comprehensive Cancer CenterP2/3BB (65)
Motixafortide
Pancreatic Adenocarcinoma
Gulam ManjiP2BB (65)
Durvalumab
Pancreatic Adenocarcinoma
Jonsson Comprehensive Cancer CenterP2BB (64)
Immunoglobulin G1, Anti-(Human 5'-Nucleotidase) (Human Monoclonal Medi9447 Heavy Chain), Disulfide With Human Monoclonal Medi9447 .Lambda.-Chain, Dimer
Pancreatic Adenocarcinoma
M.D. Anderson Cancer CenterP2BB (64)
Nivolumab
Pancreatic Adenocarcinoma
Mayo ClinicP2BB (64)
Veliparib
Pancreatic Adenocarcinoma
National Cancer Institute (NCI)P2BB (64)
Cyclophosphamide
Pancreatic Adenocarcinoma
Zhejiang Provincial People's HospitalP2B (63)
Dasatinib
Pancreatic Adenocarcinoma
OHSU Knight Cancer InstituteP2B (63)
Metformin
Pancreatic Adenocarcinoma
City of Hope Medical CenterP2B (63)
Pembrolizumab
Pancreatic Adenocarcinoma
Mayo ClinicP2B (63)
Huaier Granule
Pancreatic Adenocarcinoma
Xi'an Jiaotong UniversityP4B (62)
Panitumumab
Pancreatic Adenocarcinoma
SWOG Cancer Research NetworkP3B (62)
Niraparib
Pancreatic Adenocarcinoma
Abramson Cancer Center at Penn MedicineP2B (61)
S-1
Pancreatic Adenocarcinoma
Cancer Institute and Hospital, Chinese Academy of Medical SciencesP2/3B (61)
Carboplatin
Pancreatic Adenocarcinoma
Seagen, a wholly owned subsidiary of PfizerP2B (60)
Hydroxychloroquine
Pancreatic Adenocarcinoma
HonorHealth Research InstituteP2B (60)
Ipilimumab
Pancreatic Adenocarcinoma
Abramson Cancer Center at Penn MedicineP2B (60)
Losartan
Pancreatic Adenocarcinoma
Colin D. Weekes, M.D., PhDP2B (60)
Sargramostim
Pancreatic Adenocarcinoma
Barbara Ann Karmanos Cancer InstituteP1/2B (60)
Cetuximab
Pancreatic Adenocarcinoma
Revolution Medicines, Inc.P2B (59)
Tislelizumab
Pancreatic Adenocarcinoma
Indaptus Therapeutics, IncP2B (59)
Adriamycin
Pancreatic Adenocarcinoma
OHSU Knight Cancer InstituteP2B (58)
Decitabine
Pancreatic Adenocarcinoma
Luca CardoneP2B (58)
Immunoglobulin G1 [De-C-Terminal-Lysine], Anti-(Human Cc Chemokine Receptor Ccr8) (Human-Mus Musculus Monoclonal Bms-986340 ?1-Chain), Disulfide With Human-Mus Musculus Monoclonal Bms-986340 ?-Chain, Dimer
Pancreatic Adenocarcinoma
Mayo ClinicP2B (58)
Vcn-01
Pancreatic Adenocarcinoma
Theriva Biologics SLP2B (58)
Zolbetuximab
Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.P2B (58)
Atebimetinib
Pancreatic Adenocarcinoma
Immuneering CorporationP3B (57)
Atezolizumab
Pancreatic Adenocarcinoma
Rain Oncology IncP3B (57)
Crgd-Zw800-1
Pancreatic Adenocarcinoma
Leiden University Medical CenterP2B (57)
Glucosylifosfamide Mustard
Pancreatic Adenocarcinoma
Eleison Pharmaceuticals LLC.P3B (57)
Kinisoquin™
Pancreatic Adenocarcinoma
Quercis Pharma AGP3B (57)
Mgnp
Pancreatic Adenocarcinoma
Immuneering CorporationP3B (57)
Setidegrasib
Pancreatic Adenocarcinoma
Astellas Pharma Global Development, Inc.P3B (57)
Spartalizumab
Pancreatic Adenocarcinoma
SOLTI Breast Cancer Research GroupP3B (57)
Zoldonrasib
Pancreatic Adenocarcinoma
Revolution Medicines, Inc.P3B (57)
TANCIN
Pancreatic Adenocarcinoma
OHSU Knight Cancer InstituteP2CCC (54)
Zimberelimab
Pancreatic Adenocarcinoma
Jonsson Comprehensive Cancer CenterP1/2CCC (54)
Adenovirus 5/F35-Human Guanylyl Cyclase C-Padre
Pancreatic Adenocarcinoma
Thomas Jefferson UniversityP2CCC (53)
Aspirin
Pancreatic Adenocarcinoma
German Cancer Research CenterP2CCC (53)
Catequentinib
Pancreatic Adenocarcinoma
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolP2CCC (53)
Cediranib
Pancreatic Adenocarcinoma
National Cancer Institute (NCI)P2CCC (53)
Defactinib
Pancreatic Adenocarcinoma
Washington University School of MedicineP2CCC (53)
Showing 1 to 50 of 185 assets
PreviousPage 1 of 4Next